DailySpaceOB Holdings Berhad
0327 · ACE Market创业板（ACE Market） · annual reports 2025 to 2025, 141 entries read2025 至 2025 年报，共读出 141 条
The company这家公司
OB Holdings Berhad is principally involved in providing manufacturing services of fortified food and beverage (F&B) and dietary supplements to third-party brand owners, as well as the manufacturing, sales and marketing of fortified F&B and dietary supplements under its house brands.OB Holdings Berhad 主要为第三方品牌商提供强化食品和饮料以及膳食补充剂的制造服务，并以自有品牌制造、销售和推销强化食品和饮料以及膳食补充剂。
Sources (1)出处（1）
We are principally involved in the provision of manufacturing services of fortified food and beverage (“F&B”) and dietary supplements to third party brand owners; as well as the manufacturing, sales and marketing of fortified F&B and dietary supplements under our house brands,
In FYE 2025, manufacturing services for third-party brand owners contributed RM32.50 million (59.60% of total revenue), house brand products generated RM15.77 million (28.92%), and trading and other supporting activities totalled RM6.26 million (11.48%). Customer A accounted for RM8,697,041 or 16% of total revenue.2025 财政年度，第三方品牌制造服务贡献 RM32.50 million（占总营业额 59.60%），自有品牌产品产生 RM15.77 million（28.92%），贸易及其他配套业务合计 RM6.26 million（11.48%）。客户 A 占总营业额 RM8,697,041 或 16%。
Sources (4)出处（4）
Revenue from manufacturing services of fortified food and beverages (“F&B”) and dietary supplements for third-party brand owners contributed RM32.50 million, accounting for 59.60% of total revenue in FYE 2025, versus RM31.74 million or 62.37% in FYE 2024.
House brand products generated RM15.77 million, representing 28.92% of total revenue in FYE 2025, increased from RM12.15 million or 23.87% in FYE 2024.
Revenue from trading and other supporting activities, including milk powder trading and ancillary services, totalled RM6.26 million or 11.48% of total revenue in FYE 2025, compared to RM7.00 million or 13.76% in the previous year.
Customer A 8,697,041 16
By geography in FYE 2025, Malaysia accounted for RM49.59 million or 90.94% of total revenue, while export markets contributed RM4.94 million or 9.06%, including Hong Kong at RM2.53 million, Thailand at RM1.91 million, the United States at RM0.33 million, Singapore at RM0.16 million and Taiwan at RM0.01 million.按地区划分，马来西亚在 2025 财政年度占总营业额 RM49.59 million 或 90.94%，出口市场贡献 RM4.94 million 或 9.06%，其中包括香港 RM2.53 million、泰国 RM1.91 million、美国 RM0.33 million、新加坡 RM0.16 million 以及台湾 RM0.01 million。
Sources (4)出处（4）
From a geographical perspective, Malaysia remained the Group’s largest contributor with RM49.59 million in revenue, reflecting the resilience of our domestic operations, followed by Hong Kong contributed RM2.53 million, while Thailand contributed RM1.91 million.
Other markets demonstrated steady growth, including Singapore at RM0.16 million and the United States at RM0.33 million, with Taiwan recording RM0.01 million.
Malaysia remained the Group’s core revenue contributor by geographical location in FYE 2025, accounting for RM49.59 million or 90.94% of total revenue, compared to RM46.22 million or 90.82% in FYE 2024.
Meanwhile, export revenue reached RM4.94 million or 9.06%, up from RM4.67 million or 9.18% a year earlier.
Goodone Holding Sdn. Bhd. holds 117,488,100 shares (30.00%), while Managing Director Teoh Eng Sia holds 77,069,450 shares (19.68%) and Non-Independent Non-Executive Director Madam Wong Chung Theng holds 77,069,450 shares (19.68%). Teoh Eng Sia is the spouse of Wong Chung Theng, and both are deemed interested in the shares held by Goodone Holding Sdn. Bhd. Independent Non-Executive Director Ms. Lee Bao Yu is the daughter-in-law of Teoh Eng Sia and Wong Chung Theng.Goodone Holding Sdn. Bhd. 持有 117,488,100 股（30.00%），董事经理 Teoh Eng Sia 持有 77,069,450 股（19.68%），非独立非执行董事 Madam Wong Chung Theng 持有 77,069,450 股（19.68%）。Teoh Eng Sia 与 Wong Chung Theng 为配偶，两人均被视作在 Goodone Holding Sdn. Bhd. 持有的股份中拥有权益。独立非执行董事 Ms. Lee Bao Yu 是 Teoh Eng Sia 与 Wong Chung Theng 的儿媳。
Sources (7)出处（7）
(a) Mr. Teoh Eng Sia, the Managing Director and major shareholder of the Company, is the spouse of Madam Wong Chung Theng, the Non-Independent Non-Executive Director and major shareholder of the Company.
(b) Ms. Lee Bao Yu, the Independent Non-Executive Director of the Company, is the daughter-in-law of Mr. Teoh Eng Sia and Madam Wong Chung Theng.
Goodone Holding Sdn. Bhd. 117,488,100 30.00 - -
Teoh Eng Sia 77,069,450 19.68 194,557,550 49.68(1)(2)
Wong Chung Theng 77,069,450 19.68 194,557,550 49.68(1)(2)
(2) Deemed interested by virtue of their shareholdings in Goodone Holding Sdn. Bhd. pursuant to Section 8 of the Companies Act 2016.
No. Name No. of shares % 1 Goodone Holding Sdn. Bhd. 117,488,100 30.00 2 Teoh Eng Sia 77,069,450 19.68 3 Wong Chung Theng 77,069,450 19.68
In 2025, the Corporate Manager who joined the company in 2023 was appointed Financial Controller, and a Factory Manager was appointed in July 2025.2025 年，于 2023 年加入公司的企业经理获委任为财务总监，厂房经理于 2025 年 7 月获委任。
Sources (2)出处（2）
He joined the Company in 2023 as Corporate Manager and subsequently appointed as Financial Controller in 2025, contributing significantly to IPO readiness and audit processes.
Appointed Factory Manager of OB H oldings B erhad in J uly 2025 , she now leads the Group’s factory operations, ensuring operational excellence, regulatory compliance and continuous improvement.
Revenue by business activity, 20252025 年各业务营业额占比
Sources (3)出处（3）
Revenue from manufacturing services of fortified food and beverages (“F&B”) and dietary supplements for third-party brand owners contributed RM32.50 million, accounting for 59.60% of total revenue in FYE 2025, versus RM31.74 million or 62.37% in FYE 2024.
House brand products generated RM15.77 million, representing 28.92% of total revenue in FYE 2025, increased from RM12.15 million or 23.87% in FYE 2024.
Revenue from trading and other supporting activities, including milk powder trading and ancillary services, totalled RM6.26 million or 11.48% of total revenue in FYE 2025, compared to RM7.00 million or 13.76% in the previous year.
Major events大事记
Sources (1)出处（1）
A major strategic development of commencement of construction for our new Serendah Factory in January 2024 making a cornerstone investment in the Group’s long-term growth strategy.
Sources (1)出处（1）
On 7 March 2024, Bursa Malaysia Securities Berhad has approved the admission of the Company to the official list and the listing of and quotation for its entire enlarged issued share capital of the Company on the ACE Market of Bursa Malaysia Securities Berhad.
Sources (2)出处（2）
The Company acquired the entire equity interest of Bonlife, Orient Biotech, and Orient Laboratories, for a total purchase consideration of RM27,162,600 satisfied via the issuance of 271,626,000 new ordinary shares at an issue price of RM0.10 per share.
The acquisition was completed on 21 June 2024.
Sources (1)出处（1）
(b) 120,000,000 new ordinary shares at an issue price of RM0.24 per ordinary share for a total cash consideration of RM28,800,000 for cash pursuant to its Initial Public Offering exercise on 27 September 2024.
Sources (2)出处（2）
On 4 March 2025, Orient Biotech received a letter from the solicitors acting for NOD accompanied by a sealed Writ of Summons and a Statement of Claim, both dated 28 February 2025 and issued by the Supreme Court of Victoria, Melbourne, Australia (“Court”).
Orient Biotech had filed an appearance in defence of the proceeding on 16 April 2025.
Sources (1)出处（1）
Reinforcing this positive outlook, the Group’s wholly-owned subsidiary, Orient Biotech Sdn. Bhd., signed two Letters of Intent (“LOIs”) on 2 May 2025 with CSPC Innovation Pharmaceutical Co., Ltd. and CSPC Weisheng Pharmaceutical (Shijia zhuang) Co. , Ltd.
Sources (1)出处（1）
On 30 July 2025, the Board of Directors have proposed and approved a single tier interim dividend of 0.12sen per ordinary share, amounting to dividend payment of RM469,952 in respect of the current financial year.
Revenue, profit and operating cash营业额、盈利与营运现金
Assets, equity and borrowings资产、权益与借款
20252025 年
In FYE 2025, the company issued 120,000,000 new ordinary shares at RM0.24 per ordinary share in its Initial Public Offering, raising gross proceeds of RM28.80 million, with share issuance expenses of RM1,568,355. It acquired Orient Biotech, Orient Laboratories, and Bonlife for RM27,162,600, satisfied by issuing 271,626,000 new ordinary shares at RM0.10 per share. Repayment of term loans took RM11,795,156, while borrowings drawn included RM3,095,591 from revolving credit and RM1,281,000 from bankers' acceptances. Purchase of property, plant and equipment took RM6,770,986, and dividends paid to shareholders were RM469,952.2025 财政年度，公司在首次公开募股中以每股 RM0.24 发行 120,000,000 股新普通股，筹集 RM28.80 million 毛收益，股份发行费用为 RM1,568,355。公司以每股 RM0.10 发行 271,626,000 股新普通股，支付 RM27,162,600 收购 Orient Biotech、Orient Laboratories 及 Bonlife。偿还定期贷款支出 RM11,795,156，新提取借款包括循环信贷 RM3,095,591 及银行承兑汇票 RM1,281,000。购买物业、厂房及设备支出 RM6,770,986，已付股东股息为 RM469,952。
Sources (9)出处（9）
the Company undertook a public issuance of 120,000,000 new ordinary shares at an issue price of RM0.24 per ordinary share, raising a total gross proceed of approximately RM28.80 million
(a) 271,626,000 new ordinary shares at an issue price of RM0.10 per ordinary share, in total RM27,162,600 as fully discharge of the purchase consideration for three acquisitions of subsidiaries, Orient Biotech Sdn. Bhd., Orient Laboratories Sdn. Bhd. and Bonlife (M) Sdn. Bhd.
Purchase of property, plant and equipment A (6,770,986) (5,298,585) - (33,800)
Dividends paid to shareholders (469,952) - (469,952) -
Drawdown of bankers' acceptances 1,281,000 90,000 - -
Drawdown of revolving credit facility 3,095,591 - - -
Repayment of term loans (11,795,156) (1,228,074) - -
Share issuance expenses (1,568,355) - (1,568,355) -
The Company acquired the entire equity interest of Bonlife, Orient Biotech, and Orient Laboratories, for a total purchase consideration of RM27,162,600 satisfied via the issuance of 271,626,000 new ordinary shares at an issue price of RM0.10 per share.
At year end财政年终
At year end, borrowings were RM6,777,963 (2024: RM13,961,409), comprising bankers' acceptance of RM2,695,000, revolving credit of RM3,095,591, term loans of RM752,253 and hire purchase of RM235,119. Plant and machinery carrying RM1,079,344 and bank deposits of RM152,156 were pledged as security for bank facilities. Short term investments stood at RM13,680,863. On 30 July 2025, the Board approved an interim dividend of 0.12 sen per ordinary share amounting to RM469,952.财政年终，借款为 RM6,777,963（2024 年：RM13,961,409），包括银行承兑汇票 RM2,695,000、循环信贷 RM3,095,591、定期贷款 RM752,253 及租购借款 RM235,119。账面值 RM1,079,344 的厂房及机器以及 RM152,156 的银行存款已抵押作为银行融资的担保。短期投资为 RM13,680,863。2025 年 7 月 30 日，董事会批准派发每股 0.12 仙的中期股息，总额为 RM469,952。
Sources (8)出处（8）
On 30 July 2025, the Board of Directors have proposed and approved a single tier interim dividend of 0.12sen per ordinary share, amounting to dividend payment of RM469,952 in respect of the current financial year.
Short term investments 12 13,680,863 - 13,680,863 -
The net carrying amount of plant and machinery pledged as securities for bank borrowing is amounted to RM1,079,344 (2024: RM1,349,180).
Included in deposits with licensed banks is an amount of RM152,156 (2024: RM148,467) which is pledged to the financial institutions for the banking facilities granted to the Group.
Bankers’ acceptance 2,695,000 1,414,000
Hire purchase 235,119 -
Revolving credit 3,095,591 -
Term loans 752,253 12,547,409 6,777,963 13,961,409
Still to be spent尚未支出的承诺
From the gross IPO proceeds of RM28.80 million, RM11.6 million remained unutilised, including RM4.90 million earmarked for the repayment of bank borrowings, alongside allocations for purchase of machines, marketing and advertisement, and product development expenditure. Capital commitments were RM14,490,867 for construction of factory and RM997,496 for property, plant and equipment.在 RM28.80 million 的首次公开募股毛收益中，RM11.6 million 尚未动用，包括指定用于偿还银行借款的 RM4.90 million，以及用于购置机器、市场营销与广告和产品开发支出的配额。资本承诺包括厂房建设 RM14,490,867 以及物业、厂房及设备 RM997,496。
Sources (8)出处（8）
For the avoidance of doubt, OB Holdings has yet to utilise the remaining RM4.90 million from the IPO proceeds which has been earmarked for the repayment of bank borrowings.
the Company undertook a public issuance of 120,000,000 new ordinary shares at an issue price of RM0.24 per ordinary share, raising a total gross proceed of approximately RM28.80 million
- Purchase of machines 5,000 - 5,000 Within 36 months
- Product development expenditure 900 225 675 Within 36 months
Marketing and advertisement 1,000 - 1,000 Within 24 months
Total 28,800 17,225 11,575
Construction of factory 14,490,867 13,920,646 15,488,363 13,920,646
Property, plant and equipment 997,496 -
Four years of figures四年数字
Group figures, in RM, as printed in the statements.集团数字，单位令吉，照财务报表所印。
| Group集团 | 2024 | 2025 |
|---|---|---|
| RM令吉 | RM令吉 | |
| Revenue营业额 | 50,886,193 | 54,526,149 |
| Profit before tax税前盈利 | 7,940,829 | 6,561,414 |
| Profit after tax税后盈利 | 5,500,052 | 4,579,539 |
| Net cash from operating activities营运活动所得现金净额 | 5,338,501 | 6,492,402 |
| Purchase of property, plant and equipment购买物业、厂房及设备 | (5,298,585) | (6,770,986) |
| Dividends paid to shareholders已付股东股息 | 0 | (469,952) |
| Total assets总资产 | 52,473,725 | 76,708,615 |
| Total equity总权益 | 32,304,682 | 63,645,914 |
| Borrowings借款 | 13,961,409 | 6,777,963 |
| Cash and bank balances现金与银行结余 | 3,172,503 | 8,201,800 |
| Short term investments短期投资 | 0 | 13,680,863 |
On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上，可看到它印在哪份年报的哪一页。
Said and done说过的与做到的
Only one annual report has been read so far, so there is no later report to check its plans against.目前只读了一份年报，还没有之后的年报可以对照它的计划。
What the reports leave open年报留下待看的事
- Completion of the new Serendah Factory scheduled for the first half of 2026, with business operations slated to begin in the second half of 2026.双文丹新工厂预定于 2026 年上半年完工，业务营运预定于 2026 年下半年展开。
Sources (2)出处（2）
The project remains on track for completion in first half of 2026 with business operations slated to begin in second half of 2026.
Any setbacks in completing or commissioning the new facility could limit the Group ability to expand manufacturing capacity as planned, thereby deferring anticipated revenue contributions from new product lines.
- The legal proceeding with Nature One Dairy (Hong Kong) Limited in the Supreme Court of Victoria, with a directions hearing scheduled on 7 October 2025.在维多利亚州最高法院与 Nature One Dairy (Hong Kong) Limited 的诉讼程序，指示聆讯定于 2025 年 10 月 7 日进行。
Sources (3)出处（3）
On 4 March 2025, Orient Biotech received a letter from the solicitors acting for NOD accompanied by a sealed Writ of Summons and a Statement of Claim, both dated 28 February 2025 and issued by the Supreme Court of Victoria, Melbourne, Australia (“Court”).
Directions hearing for this matter has been scheduled on 7 October 2025.
As at the reporting date, the Board would not be able to ascertain the financial and operational impacts as well as the potential liabilities arising from the Writ of Summons and Statement of Claim as no specific amount demanded was stated therein.
- Utilisation of the remaining RM11.6 million in IPO proceeds, including RM4.90 million earmarked for the repayment of bank borrowings.剩余 RM11.6 million 首次公开募股所得款项的使用，包括指定用于偿还银行借款的 RM4.90 million。
Sources (2)出处（2）
For the avoidance of doubt, OB Holdings has yet to utilise the remaining RM4.90 million from the IPO proceeds which has been earmarked for the repayment of bank borrowings.
Total 28,800 17,225 11,575
- Whether the two Letters of Intent signed on 2 May 2025 with CSPC Innovation Pharmaceutical and CSPC Weisheng Pharmaceutical progress into commercial agreements.于 2025 年 5 月 2 日与石药创新制药及石药集团维生药业签署的两份意向书能否推进为商业协议。
Sources (2)出处（2）
Reinforcing this positive outlook, the Group’s wholly-owned subsidiary, Orient Biotech Sdn. Bhd., signed two Letters of Intent (“LOIs”) on 2 May 2025 with CSPC Innovation Pharmaceutical Co., Ltd. and CSPC Weisheng Pharmaceutical (Shijia zhuang) Co. , Ltd.
Should these initiatives progress successfully, they are expected to augment the Group’s innovation pipeline and market reach.
Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-10-17.内容为公司年报所印的事实，并注明页码；不评级，不构成投资建议。生成日期 2026-10-17。